Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer (Coimbra)
Breast Cancer Female

About this trial
This is an interventional prevention trial for Breast Cancer Female focused on measuring Fertility Preservation, Reproductive Techniques, assisted, Ovulation Induction, Oocyte Retrieval, Cryopreservation, Ovary
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 and ≤ 35 years
- BMI ≥ 18 and ≤ 35 kg/m²
- Diagnosis of breast cancer
- Presence of 2 ovaries
- Signed informed consent form
- Medically fit for general anesthesia (ASA score 1-3)
- Permission of oncology team (with agreement to postpone chemo/radiotherapy for at least 2 weeks)
- Random start controlled ovarian stimulation
- AFC minimum (ie antral follicles measuring between 2-9 mm): 8 antral follicles
Exclusion Criteria:
- Age <18 or >35 years
- BMI <18 or >35 kg/m²
- Difference in AFC between the ovaries of more than 7 antral follicles
- Diagnosis of PCOS
- Previous radiotherapy and/or chemotherapy (neo-adjuvant chemotherapy included)
- Endometriose rAFS 3-4
- Allergy or reaction to the use of Elonva®, Puregon®, Orgalutran®, Pregnyl® Gonapeptyl®, Decapeptyl® or letrozole in the past
Sites / Locations
- Universitair Ziekenhuis Brussel
- UZ GentRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
Group 1: right ovarian biopsy
Group 2: left ovarian biopsy
Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.